Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Treatment deviations and their impact on outcomes in head and neck cancer

Davide Smussi • 24 Oct 2026
ESMO 2026
Head and Neck Cancer

Davide Smussi, MD, ASST Spedali Civili di Brescia, Brescia, Italy, comments on the main reason for treatment deviation in a patients with head and neck squamous cell carcinoma (HNSCC), which was the multidisciplinary team (MDT) judgment due to high disease burden and nodal burden, leading to the need for induction chemotherapy in some cases. Deviating from clinical guidelines can have a detrimental impact on patient survival, although the absence of baseline information on comorbidities is a potential confounding factor. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Davide Smussi

AI-assisted audit of guideline adherence in head and neck cancer
1:12
AI-assisted audit of guideline adherence in head and neck cancer
Davide Smussi • 24 Oct 2026
Using artificial intelligence to assess adherence to oncology guidelines
0:52
Using artificial intelligence to assess adherence to oncology guidelines
Davide Smussi • 24 Oct 2026

Related Videos

AI-assisted audit of guideline adherence in head and neck cancer
1:12
AI-assisted audit of guideline adherence in head and neck cancer
Davide Smussi • 24 Oct 2026
Using artificial intelligence to assess adherence to oncology guidelines
0:52
Using artificial intelligence to assess adherence to oncology guidelines
Davide Smussi • 24 Oct 2026
QoLATI/DAHANCA34: QoL after TORS vs IMRT in early-stage oropharyngeal cancer
1:10
QoLATI/DAHANCA34: QoL after TORS vs IMRT in early-stage oropharyngeal cancer
Hani Channir • 25 Oct 2026
Balancing toxicity and long-term QoL in HPV-positive oropharyngeal cancer
1:04
Balancing toxicity and long-term QoL in HPV-positive oropharyngeal cancer
Hani Channir • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals